Coronavirus (Covid-19): Latest updates and information
Skip to main content Skip to navigation

COVID-19 Updates

R&IS continues to provide a full service, whilst working remotely in line with University guidance. R&IS service users should continue to liaise with their nominated departmental contacts using existing University of Warwick telephone numbers, email addresses and Microsoft Teams.

Should any R&IS service users encounter difficulties accessing support, please contact Karen Julian (024 765 24760) or Dr Catherine Cochrane (07823 362 145).

Research Ethics and Sponsorship Committees

Research Ethics and Sponsorship Committees continue to operate as normal. Meeting dates can be found below:

All Research Governance and Ethics Committee dates can be viewed on the Committee Timetable webpage.

Funder Updates

Below is some guidance issued by funding bodies in light of the recent COVID-19 outbreak. This page will updated as we hear from funders regarding their policies, measures and advice. Please find Covid-19 external funding calls here.

The Academy of Medical Science will continue to support and champion the UK's best medical and health researchers and work to ensure their voices are included in the discussions and important decision-making ahead.

Their Fellowship, including the Chief Medical Officer, Professor Chris Whitty, and Government's Chief Scientific Adviser, Sir Patrick Vallance, are leading the UK scientific response to the global Covid-19 pandemic.

The Academy's President, Professor Sir Robert Lechler PMedSci, commented:

“I applaud the Government’s approach of putting advice and evidence from world leading experts front and centre of their plans to deal with the global Covid-19 emergency.

“Uncertainty is inevitable in the coming months: it is amazing how much we have learnt already about a virus that emerged just a few months ago. Science thrives on debate and it is often the interaction of conflicting views and challenge that drives progress. However in an epidemic situation, like the one we are facing, people want certainty and firm reassurance. Trustworthy advice, from credible experts can quickly be politicised. Scientists bear a strong responsibility here and must work to ensure the public have access to the latest reliable evidence whilst at the same time maintaining awareness of its impact in the ongoing societal debate.”

Please visit the Academy of Medical Sciences website for further information and guidance.

AHDB is aware the ongoing situation regarding coronavirus has significantly impacted the research and innovation community and the nature of these impacts may evolve and increase over the coming weeks and months. There will clearly be major impacts of the coronavirus outbreak on many of the research projects supported by AHDB. AHDB is working to understand the nature of any impacts on our funded projects as the situation evolves. This work is ongoing. Thank you to all those who have helped us identify potential issues so far. We will continue to work with the institutions affected individually to understand the full extent of the issues and develop specific plans for how to respond.

Our priority is the safety and well-being of people, both our own staff and those supported by our research funding and studentships.

AHDB will seek to take a pragmatic approach that enables research to be continued in the most effective way possible without impacting on the health or well-being of the research teams but we recognise that in many cases a delay is inevitable. Researchers may find themselves unable to complete essential tasks and/or experiments in order to meet contractual deadlines, for example due to departmental or institution closures, or their own or colleagues’ illness or need to self-isolate.

In some circumstances, no cost modifications to research projects will be approved. In specific circumstances, AHDB-funding may be extended. The specific approach to the most likely impacts is detailed below.

Further information will still be provided through your established relationships.

Action in the event of inability to deliver research

We recognise that illness, prolonged self-isolating, travel restrictions, and limitations on access to research or other premises may undermine the ability to complete research contracts within the funded period. In these cases, an extension will be considered. Where an increase in cost is likely to be incurred to avoid severely limiting the value of the outputs, and where researchers are at risk of no payment due to contractual payments terms e.g. milestones, AHDB will consider a funded extension, and continuity of payments where appropriate, and will be assessed on a case-by-case basis with the research manager and senior AHDB team. In other cases, a no-cost extension will be applied.

Procedure for approval of extensions

Please keep AHDB informed of any issues as they arise. In the first instances, and at the earliest opportunity, please write to the AHDB manager responsible for the project alerting them to any factors likely to result in a request for an extension. AHDB will determine the most appropriate course of action in consultation with the principal investigator and, if appropriate, a contract variation will be issued.

Institution-wide discussions are also taking place between AHDB Directors and key delivery partners, so please keep the appropriate senior colleague in your organisation informed in parallel.

The British Academy encourages award holders to investigate possible alternative ways of continuing to progress their research. However, they understand that the outbreak may impact on the activities associated with some awards and will treat all requests for no-cost extensions to awards and requests for virement of funding between cost headings sympathetically. These should be requested in the usual way.

Please visit the British Academy website for further information and guidance.

The latest British Heart Foundation statement, issued on 1 May, 2020, can be found on their website.

Update issued on 24 March, 2020:

The British Heart Foundation has issued the following comunication:

"The rapidly evolving situation with COVID-19 brings significant challenges for the BHF research community, as it does in all walks of life. At this extraordinary time, everyone’s immediate focus should rightly be on the safety and well-being of themselves, their families and those that they are responsible for.

We recognise that COVID-19 is likely to have a substantial impact on the research and researchers we are funding, and the research-related activities we have agreed to support. Although the full implications will take some time to become clear, we intend to address the issues that arise as sympathetically and flexibly as possible."

Further specific information and guidance can be found on the following BHF webpages:


Please refer to these BHF webpages regularly, as their position may change as the COVID-19 outbreak evolves.

If you have any queries or comments, please email

The following message has been issued by CRUK's Executive Director of Research & Innovation, Iain Foulkes:

CRUK Research Update: 14 January, 2021

"With the UK entering another lockdown, we’re aware of the potential strain on clinical services and impact on research that this current wave of the pandemic brings. We’ve recently updated our Coronavirus (COVID-19) guidance for grantholders about the re-deployment of clinical researchers to support NHS services and clinical trial recruitment. We understand this continues to be a period of significant disruption for you and your teams. We’ll continue to support you through this period and help minimise the impact of your research activities by offering as much flexibility as we can.

We’re committed to advancing research into therapies, diagnostics and technology for patient benefit. To do this, the knowledge and expertise of researchers must combine with the capability and scale of the pharmaceutical and biotechnology industry to develop and launch products into the market. Together with our clinical partnership lead, George Tzircotis, and our chief business officer, Tony Hickson, we’ve co-authored a Nature Reviews Cancer Comment article explaining how and why Cancer Research UK (CRUK) can facilitate these crucial collaborations between academia and industry in a way that safeguards the interests of the research community.

Lastly, I’m pleased to share the great news that Ian Walker has been appointed Executive Director of Policy, Information and Communications at CRUK and is due to start in March 2021. Ian joined in 2006 and has since held various roles, most recently as Director of Research where he has been responsible for our external research portfolio spanning discovery science, translational and clinical research. He has been a great colleague and I’m so pleased that he is joining the executive board at such an important time for the organisation. Please join me in congratulating Ian on this new appointment.

While 2021 has started with very mixed news with concern about the spread of the highly infectious new strain of the virus, and now a national lockdown, there is considerable hope as the mass vaccination programme gets underway."

Iain Foulkes

Executive Director, Research & Innovation

The following message has been issued on behalf of Dr Elizabeth Robertson, Director of Research, Diabetes UK:

"Thank you to those who have responded so quickly to my email regarding the impact of COVID-19 on your research projects. It’s clear that that many of you will be putting your clinical and wet lab research on hold for the coming weeks, I’m sure that this is a very stressful time for you all.

Currently, we are collating your responses and discussing the best way to proceed during this unprecedented time. We will be responding to each of you individually as soon as possible, but please be assured that we will be flexible with project extensions."

Please visit the Diabetes UK website for further information and guidance.

Given government’s advice regarding non-essential travel and homeworking, EPSRC and UKRI as a whole have advised all staff to work from home until further notice. Please continue to connect with your key contacts and the wider teams in the normal way via email, phone and videoconference.

There will inevitably be impacts on institutions’ ability to undertake research already funded and/or underway, as well as to engage in the proposal application and assessment process. EPSRC is currently working across UKRI on plans to enable the business to continue, and will keep you informed as these develop.

Please do keep EPSRC informed of developments and impacts you see arising related to the research and training programmes they support, and any other aspects of working with them. This will enable them to shape their plans in a way which best addresses the needs of the research community.

UKRI is following HM Government’s advice in decision making and a page has been established to communicate news related to the coronavirus situation for those whose research EPSRC supports. EPSRC will continue to communicate directly with you as strategic partners to highlight any key developments and what they mean for you.


ERC is taking steps to try to minimise the disruption caused by the COVID-19 pandemic on its operations, while ensuring the safety and wellbeing of their staff and the people with whom they work. The majority of staff are now working remotely and grant management activities are continuing as usual.

Please visit the ERC website for further information and guidance.

In response to the Covid-19 crisis, some European Union (Horizon 2020) call deadlines have been extended to give more time for applicants to prepare their proposals. A full list of these calls can be found on the H2020 website.

European Research Area (ERA) Corona Platform Launched

The European Commission has launched the European Research Area (ERA) Corona Platform on its Funding & Tenders Portal to make information related to the COVID-19 outbreak and its impact on Horizon 2020 grants available in a single place.

The page is still under construction, but already includes links to the COVID-19 FAQs, a list of Horizon 2020 deadlines that have been extended and links to other useful resources. In the future, it will also include links to the relevant pages of EU Member States and will be a one-stop-shop for applicants and beneficiaries of Horizon funds looking for information about the COVID-19 outbreak.

In the meantime, UKRO subscribers will find all relevant information on the COVID-19 and EU Funding section of the UKRO Portal, which is updated daily.

The Gordon and Betty Moore Foundation has issued the following statement:

"In these uncertain times confronting COVID-19, all of us, along with our families, our neighbours, and our colleagues at work, are dealing with this pandemic in our personal and professional lives. As a grantee of the Moore Foundation, you are in our thoughts. We recognise that this health crisis is likely affecting everything you are trying to accomplish.
Your wellbeing is our main concern, and we aim to be a reliable partner in these difficult times. Like many organisations, we are functioning on a work-from-home basis, intending to stay in close communication with one another and with our grantees.
As you get a better handle on how conditions may impact your work with the foundation, please let us know how we can help. Your Moore Foundation will continue to provide the time, flexibility, and resources you need to achieve our shared goals."

The HRA has published guidance that relates to Research Ethics Committee (REC) and NHS arrangements. This is a rapidly evolving situation and guidance will be updated in response to feedback.

Please visit the HRA website for further information and guidance.

Innovate UK has business continuity measures in place and is continuing to operate.

If you have an Innovate UK award:

Contact your monitoring officer

If you are an Innovate UK award recipient, also contact your Innovate UK monitoring officer, who will keep us informed and allow us to assess if we can offer support too. The earlier you speak with your monitoring officer, the easier it will be to understand your issues and find potential solutions.

Speak to your local EEN advisor

Specialist advisers from the Innovate UK Enterprise Europe Network (EEN) team, located regionally, are also there to help and support you.

Please visit the Innovate UK website for further information and guidance.

The Leverhulme Trust will continue to take its usual pragmatic approach, and will allow reasonable changes to budget lines and/or no-cost extensions to grants, to enable grant holders to manage their research in the best way for their circumstances.

Please visit the Leverhulme Trust website for further information and guidance.

MRC is aware that due to the coronavirus outbreak, that there is increased demand on the clinical services, and that you may be asked to undertake additional clinical sessions. Whilst they expect Fellows to fully concentrate on their research, they understand that this is an exceptional situation and are fully supportive of any decision you may take to reduce the time spent on your research during the outbreak.

If you do decide to reduce the time spent on your research, MRC will agree an extension to your award. They will also consider supporting some modest consumable/running costs, e.g. maintaining animal colonies during the absence period. As the situation is currently uncertain, please do not submit an extension request until you return to your research full-time. However, you may wish to consider whether a suspension of your award would be appropriate.

Please visit the MRC webpages for information and guidance on grant suspensions and extensions.

The MRC Executive Chair, Fiona Watt, has also published an update in relation to the current situation.

When delays occur because the applicant or recipient organisation is officially closed or unable to submit grant applications due to the effects of COVID-19, the NIH will consider accepting applications late, on a case-by-case basis, under certain circumstances.

Full NIH policy on grant applications.

The NIH has also introduced flexibilities applicable to NIH applicants and recipients where the entity is conducting research activities related to or affected by COVID-19, relating to:

  • Pre-award costs
  • Extension of post-award financial and other reporting
  • Prior approval requirement waivers
  • Cost-related flexibilities/expenditure of award funds
  • Extension of closeout
  • Extension of single audit submission

The following message has been issued by NIH's Deputy Director of Extramural Research, Mike Lauer:

Responding to Frequent Questions on Flexibilities Related to NIH Funding and COVID-19: 26 March, 2020

"The public health emergency due to COVID-19 is causing difficulties in many aspects of our lives. My colleagues and I here at NIH are well aware of the challenges being felt in the research community as institutions are closing, people are being asked to practice social distancing, and resources and attention are justifiably focused on public health needs. We are listening to your concerns and are working quickly to develop answers to your many questions.

We recently updated our Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients website with a slew of additional FAQs, new funding opportunities, as well as the video message from me, below, where I address some of the most common questions.

Since yesterday’s recording of this video, in response to community concerns about their ability to submit applications in a timely manner, we have published a notice announcing that grant applications submitted late for due dates between March 9, 2020, and May 1, 2020, will be accepted through May 1, 2020. This notice applies to all relevant funding opportunity announcements, including those that indicate no late applications will be accepted.

A cover letter providing a justification is not required. NIH will be extending the expiration date of most FOAs expiring between now and May 1. Be sure to read the notice carefully for details.

I encourage you to monitor our website frequently. To help you identify updated content, the page now includes a link to page update history so you can easily see what’s new."

Mike Lauer

Deputy Director of Extramural Research

Clinical and academic health and care professionals currently funded by NIHR who are working on topics other than COVID-19 should prioritise frontline care, where requested to do so by their employing organisations. Similarly, research staff with other relevant skills, such as pharmacists and laboratory technicians, should also prioritise support to frontline care. In addition, researchers should consult with their employers to make facilities which currently support research studies available for frontline care.

Please visit the NIHR website for further information and guidance.

The Nuffield Foundation's priorities during the COVID-19 pandemic are to support staff, grant-holders and the young people who participate in their student programmes, as well as to fund research that addresses the wider social significance of the pandemic.

The organisation has published full detail of the response and measures on their website, including information for grant-holders.

Please visit the Nuffield Foundation website for further information and guidance.

The Rosetrees Trust has extended deadlines for its schemes from end of March until the end of April. This may have impact for applicants to the 'Enterprise Fellowships' scheme in particular.

Please visit the Rosetrees Trust website for further information and guidance.

Following the UK government’s advice on the COVID-19 pandemic, the Royal Academy of Engineering has closed its London premises until further notice.

All Academy meetings will be hosted virtually, and all Academy events are being postponed or cancelled until the end of April 2020, unless they can be held online. Events between May and August will be assessed on a case by case basis and the Academy will provide updates on forward plans as soon as practicable.

Please visit the Royal Academy of Engineering website for further information and guidance on the above.

The Academy has also published COVID-19 advice for awardees. Please visit their dedicated webpage for more information.

The Royal Society's offices are closed as of Wednesday 18 March. All staff are working remotely and are contactable via email and telephone channels. All funding programmes and calls currently remain open for applications in line with advertised dates. The Royal Society will endeavour not to make any changes to application deadlines, interview dates or decision dates. Please visit the Royal Society website for further information and guidance.

Update in relation to Newton International Fellowship Deadline:

On 24 March, the following statement was issued by the Royal Society:

"We understand that with organisations closed and new working from home arrangements, applicants may not be able to meet the current deadlines for our Newton International Fellowship call (deadline Thursday 26 March). We will therefore be extending the deadline for Newton International Fellowships as follows:

Newton International Fellowship extended deadline: Wednesday 8 April 3pm (BST).

If you have any queries regarding submitting a grant application to this call, please contact

For further information about the Society's response to the Coronavirus pandemic with regards to grants programmes, please visit their regularly updated information page."

The specific guidance and management strategy is as follows:

2019 trials that were established in 2019 and due to be completed in 2020
  • Most of the field work associated with these trials will have been completed in 2019 and these projects should not encounter any field issues
  • In the small number of cases where final assessments have yet to be carried out in 2020, we would advise that the contractor should risk assess the final field tasks with their staff and host site (if this is a third party) and should only continue if they are satisfied that any risks can be managed safely
    • We accept that it may be necessary to delay or abandon the final assessments if these cannot be delivered safely and the SCEPTREplus programme will cover all costs incurred to date, including interim reporting if some useful regulatory data have been collected
  • It is anticipated that report writing can be carried out remotely and it should be easier to manage this part of the process with minimal risk, however it is understood that delays may be encountered due to illness of the researcher or key service providers, such as statisticians
    • We may consider the suspension of the current penalty clauses for delayed reports if the SCEPTREplus Team has been provided with full details of any delay and the reasons for any delay as soon as it may arise and prior to the expiry of any deadline.
  • All face to face KE plans will be suspended and may be replaced with remote activities or other strategies under the direction of the AHDB KE Team and related costs under the existing contract will be managed in accordance with the revised plan
2020 trials that were established prior to 31/03/20
  • The contractor is advised to complete a documented risk assessment to determine their ability to complete the trial as set out in the protocol considering:
    • Impact of illness on key workers
    • Staff cover in the event of absence of key workers
    • Willingness of the site host to continue with the trial (if relevant)
    • Ability to manage the trial with no or minimal input from the host
    • Likelihood that access arrangements will remain for the duration of the trial
  • Please remember that the position of the host farm may change as the disease spreads:
    • It is highly likely that some businesses may suspend all third-party access – this has already happened in many cases
    • The motivation of host farms to support trials and use the results will be greatly reduced as they focus on day to day challenges
    • The priority of the host farms must be to maintain their normal production during this difficult time and this must not be interrupted by any SCEPTREplus projects
  • It is anticipated that contractors should already have all the materials that they require to complete the trial if they decide that they are able to continue (eg. experimental treatments, cultures etc), but this should also be included in the risk assessment and may be another reason for suspension if availability cannot be guaranteed
  • We anticipate that most contractors will conclude that they are unable to guarantee that the project can be delivered in full due to the risks and the work should therefore be suspended with immediate effect
  • SCEPTREplus will cover all trial related costs incurred to date and we will aim to re-start the trial in 2021 on the same cost-base agreed for the 2020 trial, subject to available funds
  • Any KE activity that has been included in the plans for 2020 will need to be reviewed with the AHDB KE Team since all grower events have been suspended until further notice
  • The KE Team may wish to reallocate the funds to other KE, if appropriate, or delay activities until conditions improve
Trials that are due to be established from 01/04/20
  • The same criteria detailed above for trials that have already been established applies to any new trials that have not yet been established
  • It is not clear that AHDB will be able to access all the experimental materials required for the trials as set out in the protocol – trials must not be started if key treatments are not available
  • It is advised that full and documented risk assessment should be carried out if it is decided to continue
  • We anticipate that most contractors will conclude that they are unable to guarantee that the project can be delivered in full due to the risks and the work should not be started
  • SCEPTREplus will cover any costs incurred to date with trial planning and we will aim to re-start the trial in 2021 on the same cost-base agreed for the 2020 trial, subject to available funds Impact on CP165
  • The SCEPTREplus PSG has already approached AHDB to request that CP165 is extended by 12 months to 01/04/22 to provide additional time to complete any deferred trials
  • We acknowledge that there may be some additional costs for the work that needs to be abandoned together with the management of the project and it is hoped that additional funding may be provided to cover these costs so that the suspended programme can be delivered in 2021/22
  • We recognise that the risks from the virus may result in the suspension of most of the planned field work which will have a significant impact on the cash flow of contractors and may result in healthy staff being laid-off
  • It may be possible to reallocate some SCEPTREplus funds to support desk-based reviews and related studies that address key priority areas (eg. identification of new integrated strategies to manage key targets)
    • This will be subject to approval from the PSG and support from AHDB
    • Any new projects will need to be delivered by specific individuals with minimal face to face contact (eg. home-based)
    • These projects should not have any specific time restrictions - ie. there needs to be sufficient time to complete the work and deliver the results to support the plans for the 2021 programme after allowing for any periods of unforeseen absence through illness (most projects will need to be delivered by 31/03/21 at the latest, but this will be agreed on a project by project basis)

We understand that the delay in completing some of the planned projects may create issues for growers with the loss of key products, but we will endeavour to manage this with the regulators and the crop protection sector. SCEPTREplus recognises that Covid-19 may have a major impact on our planned programme for 2020. We are keen to minimise impact on both growers and researchers, but our primary objective is to protect the health of everyone involved in the SCEPTREplus programme. We will seek to continue our work and activities through remote communications as far as this is possible.

The Turing’s offices at the British Library is closed from 17 March until further notice. The Institute is using a suite of online collaboration tools and platforms to continue to facilitate conversation and engagement with colleagues, universities, businesses, third sector organisations and the public. Please visit the Turing website for further information and guidance.

The following message has been issued by the Turing's Institute Director, Adrian Smith:

Covid-19 research update: 26 March, 2020

"First and foremost, I hope you and your loved ones are keeping healthy during these challenging times.

I want to ensure the Institute is willing and able to play its part at the forefront of the fight against this global pandemic and explore opportunities to provide immediate frontline support to the UK’s efforts to tackle Covid-19.

To this end, in recent weeks myself and our Programme Directors, most notably Programme Director for Health and Medical Sciences Chris Holmes have been personally engaged in a number of positive discussions with the NHS and others about how our vibrant research community could best support this effort. A number of new opportunities and strands of work are now beginning to emerge, although the situation is fluid and subject to many moving parts.

We are incredibly grateful for all the offers of support and interest to underpin this work while the projects are coming together. It is heartening to see so many from our community wanting to be involved and tackle these critical challenges head on. That said, I know you will understand that it’s also important to be especially sensitive and not put additional burden on the front-line NHS and others. For this reason, our offers of support require a rapid but well-coordinated approach. We are currently working on the detail of how best implement this across the research community, drawing on our university partners and networks, and will be in touch as soon as we can.

In the short-term, we have created a ‘Covid-19’ channel on Slack to be used day-to-day to share ideas and discuss opportunities for the Turing community to develop research around coronavirus. We are also looking at ways to encourage further discussion and collaboration and highlight the Institute’s work in this area.

If you have thoughts on any of these matters, please share them on Slack here in the first instance. This channel will be regularly monitored and the feedback shared with the team.

Please be assured that a great deal of work is going on now to establish the most useful way the Turing, as the UK’s national institute for data science and AI, can help immediately. There will, undoubtedly be longer term projects and the Turing’s Research Leadership will be in touch very soon to take this forward with your support.

I also hope to take part in an all-staff virtual address very soon and will shortly share more details. Continue to do what you do best as best you can - carry on your important work and research and I look forward to hearing if you will be able to participate in this collective effort."

Adrian Smith

Institute Director

UKRI is aware that the ongoing situation regarding coronavirus has significantly impacted the research and innovation community. Following government advice, UKRI office-based staff are working from home. If you need to contact one of the teams, please do so via email and/or mobile phone in the usual way.

UKRI has consolidated guidance into a new website.

This also includes a dedicated section on the impact of Coronavirus on UKRI-supported research, updated on 3 April, 2020.

UKRO has a new section on the web portal to allow subscribers to easily access the latest announcements and advice on the COVID-19 outbreak.

The following articles are available on the portal:
  • 45 New COST Actions Awarded: 45 new COST Actions have been awarded to networks of researchers from around the world. Full Article...
  • Fast Track Access to Research Infrastructures as Response to COVID-19: The Association of European-level Research Infrastructure Facilities has set up a page consolidating information on Research Infrastructures that provide specific services in response to the COVID-19 pandemic. Full Article...
  • UK Entry Visa Extensions in Response to the COVID-19 Outbreak: The Home Office has announced visas extensions for those who are currently unable to return home as a result of COVID-19. Full Article...
  • Societal Challenge 1 - Deadlines Extended: The European Commission has further extended the SC1 'Health, demographic change and wellbeing' calls deadlines, until 4 June and 18 June. Full Article...
  • Open Access Publishing Platform Contract Awarded: The European Commission has awarded a contract for the setting up of an Open Access Publishing Platform, as a free service for Horizon 2020 and Horizon Europe beneficiaries. The platform is expected to launch in early 2021. ​ Full Article...
  • UKRO Factsheets on Open Science: Two new factsheets on the topic of Open Science have been launched on the UKRO Portal. Full Article...
  • Horizon Impact Award 2020: Deadline Extension: The European Commission have extended the deadline for the 2020 Horizon Impact Award. Full Article...
  • Additional COVID-19 Guidance for MSCA Beneficiaries: The European Commissions has published additional guidance for MSCA beneficiaries in light of COVID-19. Full Article...
  • UKRO COVID-19 Webinar Follow-up: Answers to Questions Asked - Q9 Updated! UKRO would like to provide clarifications on some of the issues­ raised by participants in its 'COVID-19 and EU Funding' webinar. Updated with response from REA regarding volunteering (Question 9). Full Article...

Please visit the UKRO website for further information and guidance.

The Wellcome Trust has published its approach to managing grants through the COVID-19 pandemic on the website.

In summary:

  • The Wellcome Trust is not currently making changes to deadlines or committee dates, although they will be running some committees remotely. They can approve the submission of applications for you, but must have permission beforehand
  • Where someone is called away to work on the Coronavirus response for one month or more (for example carrying out clinical duties) they will provide extensions and supplements
  • Where there are other impacts, they will look to minimise the impact on funded research activities wherever possible. This may be extensions and/or supplements, if there is no insurance

All Wellcome Trust staff who work on grants and applications can work from home and will be contactable by email and phone as usual. Staff are equipped with Teams and BlueJeans for conference calls, and will be able to continue our work with you as best we can in these unusual circumstances.

Please visit the Wellcome Trust website for further information and guidance.

For REF-specific updates, please visit the R&IS REF webpage.
For information on the operational status of Research Technology Platforms (RTPs), please visit the RTP Status webpage.